HDAC inhibitors: A novel approach to hyperglycaemia management and treatment

Abstract

The field of genomics plays a prominent role in treatment of numerous chronic diseases. Diabetes is a persistent metabolic disorder. Current studies and reports have emphasised the importance of several epigenetic markers in the therapy of type 2 diabetes. Histone Deacetylases(HDAC) enzyme regulate the structure of chromatin and the transcription of genes in the nucleus that produce proteins that regulate metabolic processes in the body. It influences gene expression primarily by removing an acetyl group from its precursor protein, and it regulates acetylation metabolic enzymes in mitochondria and cytoplasm. The balance between histone acetylation and deacetylation is an epigenetic layer that modulates gene expression. Gene transcription is associated with histone acetylation induced by histone acetyl transferases, whereas histone hypoacetylation influenced by histone deacetylase activity is related with gene silencing. This review focuses on the role of histone deacetylase inhibitors as a newly discovered treatment for diabetes and its impediment, defining their use in preventing insulin resistance, cell death, and cytokine-mediated attack on pancreatic cells.

Keywords

• HDAC inhibitor
• β-cell function
• Insulin signalling
• Diabetes mellitus